Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

GlaxoSmithKline Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (243)
ARTG (106)
Australian public assessment report (AusPar) (42)
Prescription medicine registration (22)
Designation or determination (5)
Prescription medicine decision summary (3)
Prescription medicine evaluation (3)
Face mask cancellation (1)

Date

2026 (1)
2025 (26)
2024 (13)
2023 (18)
2022 (61)
2021 (12)
2020 (59)
2019 (30)
2018 (27)
2017 (24)
2016 (11)
2015 (49)
2014 (21)
2013 (9)
2012 (6)
2011 (4)
2010 (7)
2009 (3)
2008 (6)
2007 (4)
2006 (3)
2005 (4)
2004 (1)
2003 (3)
2002 (1)
2001 (1)
2000 (3)
1999 (1)
1998 (5)
1997 (4)
1995 (1)
1991 (6)

Search

Sponsor content

425 result(s) found, displaying 191 to 200

Lamictal Dispersible Tablets 5mg Cancelled under Section 30(1)(c) of the Act

15 July 2020

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
Lamictal Dispersible Tablets 50mg Cancelled under Section 30(1)(c) of the Act

15 July 2020

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
Lamictal Dispersible Tablets 200mg Cancelled under Section 30(1)(c) of the Act

15 July 2020

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
Valtrex Tablets Cancelled under Section 30(1)(c) of the Act

15 July 2020

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
Zeffix 100mg Tablets Cancelled under Section 30(1)(c) of the Act

15 July 2020

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
Naramig Tablets 2.5mg Cancelled under Section 30(1)(c) of the Act

15 July 2020

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
TYKERB Lapatinib 250mg (as ditosylate monohydrate) tablets bottle pack (EXPORT ONLY) Cancelled under Section 30(1)(c) of the Act

15 July 2020

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
TYKERB Lapatinib 250mg (as ditosylate monohydrate) tablet Blister Pack (EXPORT ONLY) Cancelled under Section 30(1)(c) of the Act

15 July 2020

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
MENJUGATE SYRINGE meningococcal C conjugate vaccine 10microgram/0.5mL powder for injection with diluent Cancelled under Section 30(1)(c) of the Act

18 May 2020

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
AusPAR: Mepolizumab

5 March 2020

Australian public assessment report (AusPar)

Australian Public Assessment Report for Mepolizumab

Pages

First page
Previous page
…
Page 16
Page 17
Page 18
Page 19
Current page 20
Page 21
Page 22
Page 23
Page 24
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.